Wednesday, October 10, 2018
San Antonio Marriott River Center
101 Bowie St
SALON CDE
5:45-7:15 AM

Updates in Precision Medicine: Elevating the Treatment of Severe Eosinophilic Asthma is a 1-hour, case-based symposium that focuses on addressing the unmet needs of patients with severe asthma. Evidence from clinical trials of biologic-based therapies is reviewed to extend the recommendations from current ERS/ATS guidelines. Case scenarios are discussed to guide treatment selection based on patient characteristics, including phenotype. The use of a shared decision-making tool is explored.

Content Areas:

  • Pathophysiology
  • Differentiating severe asthma from uncontrolled asthma
  • Phenotypes
  • Biomarkers
  • Targeted biologic therapy
  • Shared decision-making

 

Faculty

Nicola A. Hanania, MD, MS
Associate Professor of Medicine, Section of Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center (ACRC), Baylor College of Medicine
Director of the Asthma Adult Clinic and Pulmonary Diagnostic Services, Ben Taub General Hospital

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor for Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania

 

Agenda

  • Updates in Clinical Trial Data
  • Updates on Guidelines
  • Clinical Implications of Recent Research
  •  Pathophysiology
    • Immunological Profiles
    • Phenotyping and Endotyping
  • Currently Available Biological Therapy
    • Clinical Profiles
      • Eosinophil
    • Mechanisms of Action
    • Administration
    • Treatment Response / Goals
  • Emerging Biological-Based Therapy
  • Questions/Answers

 

Learning Objectives

  • Describe current evidence for the use of biological-based therapies for the treatment of severe asthma
  • Differentiate biological-based therapies for the treatment of severe asthma based on patient- and treatment-related factors
  • Utilize genetic information to select the appropriate biological-based therapy for a patient with severe asthma
  • Apply updated guidance to optimally utilize biological-based therapy in patients with severe asthma

CE Statement

Target Audience

This activity was developed for pulmonologists, allergists, and other clinicians involved in the management of severe asthma.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this live meeting for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Nicola A. Hanania, MD, MS
Research Support: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron
Speaker Bureau: AstraZeneca

Reynold A. Panettieri, Jr, MD
Research Support: AstraZeneca, Bristol Myers Squibb, Genentech, Gilead, MedImmune, OncoArendi, RFIM, Sanofi/Regeneron, Theratrophix, Vertex
Consultant: AstraZeneca, Boehringer-Ingelheim, MedImmune, Novartis
Speaker Bureau: AstraZeneca, Boehringer-Ingelheim, MedImmune, Sanofi/Regeneron, Teva

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners

The following have no significant relationship to disclose:
Eugene Cullen, MD (peer reviewer)
Gregory Scott, PharmD, RPh (medical writer)

Annenberg Center for Health Sciences

Charles Willis, Director of Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by educational grants from AstraZeneca and GlaxoSmithKline.

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Our Policy on Privacy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

Contact Information

For help or questions about this activity please contact Continuing Education:

ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone  760-773-4500
Fax       760-773-4513
8 am – 5 pm, Pacific Time, Monday – Friday